Among all the combinations tested in serum samples based on data from CRC cell line glycoprofiling, CD151CD63 was the most promising combination; it outperformed the conventional CEA EIA and showed a significant difference between healthy + benign vs. early-stage CRC samples (p < 0.00183). Here, CEACAM5 is linked to colorectal carcinoma.